Speed’s always important in cell therapy, but for patients with aggressive conditions or unmet needs, vein-to-vein time is critical to survival. Enter DAR-T™. For CAR-T innovators interested in exploring new, advanced manufacturing technologies, DAR-T™ delivers autologous CAR-T cell therapy manufacturing with a batch manufacturing time of just 3 days.
Build Your Resilience™
Think of Build Your Resilience™ as your answer to choosing a trusted secondary supplier. Decide which state of readiness fits your program needs best between three targeted levels of readiness that span across access to our procurement, logistic, commercial, and quality teams and programs with no annual commitment required.
Essential AAV & LVV
Secure a 200L batch of GMP AAV or LVV vector in under 12 months using our scalable platform. As your program evolves and your scale increases, we’ll work with you to meet patient & commercial demands thanks to the consistency of the bioreactor platform used from one scale to the next.
.png)
Auto-T
The Auto-T cell therapy manufacturing platform from Resilience offers therapeutic innovators a vetted and accelerated pathway to clinical trials. Auto-T is an end-to-end manufacturing and assay platform for LVV-based autologous CAR-T and TCR-T cell therapies containing all required regulatory support to get your clinical trial started within one year of signing on.
Idea to Clinic™
Getting you from ideation to clinic in record time demands a simultaneous focus on big data and small details. That’s precisely where Idea to Clinic™ comes in. It puts our processes and technologies to work at achieving a considerable ambition: to deliver your team a 30% time savings from start to finish.
SNAPLVV™
Get the right amount of lentivirus vector (LVV) just the way you need it – fast and easy. Enter SnapLVV™ — an off-the-shelf process to get your cell therapy ready for first-in-human studies without time-consuming de novo development. You plug, play, and get a single batch of material that gives you everything you need to get through your Phase I studies.
